Prognostic Factors for Hepatocellular Carcinoma Recurrence: Experience With 83 Liver Transplantation Patients  by Ataide, E.C. et al.
c
s
v
s
a
rPrognostic Factors for Hepatocellular Carcinoma Recurrence:
Experience With 83 Liver Transplantation Patients
E.C. Ataide, I.F.S.F. Boin, J.R.S. Almeida, T. Sevá-Pereira, R.S.B. Stucchi, A.R. Cardoso, C.A.A. Caruy,
and C.A.F. Escanhoela
ABSTRACT
Introduction. Orthotopic liver transplantation (OLT) is a rational therapeutic option for
early-stage hepatocellular carcinoma (HCC) providing a potential cure and improving
survival.
Methods. This retrospective study of a longitudinal cohort used an electronic database
collected prospectively from September 1997 to May 2010. The variables were gender, age
(years), and alpha-fetoprotein (AFP) level (ng/mL). In explanted livers we observed:
microvascular or macrovascular invasion, number of nodules and their largest size,
Edmondson-Steiner histological differentiation, incidental tumor transarterial chemoem-
bolization (TACE), Milan criteria, and previous down-staging.
Results. Five of 83 (6.0%) subjects including 68 (82%) males with a mean time to
diagnosis of 9 months experienced tumor relapses. Mean patient age at HCC recurrence
was 55.3 years for male and 44.6 years for female subjects. Vascular invasion was detected
in 17/83 (20.5%) subjects, namely 2% of macrovascular invasion, and 52.5% with expanded
Milan criteria due to an increased number and size of nodules in the explanted livers. An
incidental tumor was observed in 29.5% of cases. Preoperative TACE treatment was
performed in 13 (15.6%) patients. None of the patients who had a HCC recurrence had
undergone TACE. AFP level at the time of recurrence was around 1,900 ng/mL. The
predictive factor for mortality was nodule size (P  .04; hazard ratio  0.0269; confidence
interval [CI], 95% 0.0094–0.299).
Conclusion. Patients with relapses showed the worst survival and tumor size was a
predictive factor for recurrence.
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aORTHOTOPIC liver transplantation (OLT) is a ratio-nal therapeutic option for early-stage hepatocellular
arcinoma (HCC) providing a potential cure and improving
urvival.1–3 Their 75% 5-year survival rate, which is similar
to that of cirrhotics without HCC, is achieved using the
Milan criteria, namely, a single nodule 5 cm in diameter
or up to 3 nodules3 cm.4–7 Nevertheless, recurrence rates
arying from 3.5%–26% remain.5–12 Several factors related
to OLT have been implicated in tumor recurrence.3–7
Tumor size, histological grade of differentiation, both micro-
vascular and macrovascular invasion, and alpha-fetoprotein
(AFP) levels are currently the best predictors for recur-
rence after OLT.7–12 In the present study, we have de-
cribed the outcomes in terms of tumor recurrence among
series of OLT for HCC by analyzing risk factors forecurrence: AFP levels, macrovascular and microvascular
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1362nvasion, grade of differentiation, number and size of
odules, incidental nodules, and preoperative chemoembo-
ization. Our aim was to verify the survival rate, relapse rate,
nd prognostic factors among OLT patients with HCC.
PATIENTS AND METHODS
This retrospective study of a longitudinal cohort used an electronic
database collected prospectively from September 1997 to May
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HCC RECURRENCE 13632010. The inclusion criteria were as follows age older than 18 years,
OLT due to HCC, and survival of at least three months. All
patients obeyed the Milan criteria6 according to current Brazilian
law.
The diagnosis was confirmed6 using Doppler ultrasonography,
abdominal computerized tomography (CT), and magnetic reso-
nance imaging that showed arterial hypervascularization and wash-
out in the portal venous phase associated with an AFP value 400
ng/mL before 2009 and 200 thereafter. The gold standard was
liver biopsy. To exclude bone or pulmonary metastasis, we used
scintigraphy and thoracic CT. Patients who did not meet the Milan
criteria (expanded Milan criteria [EMC]) were treated by transar-
terial chemoembolization (TACE) or percutaneous alcohol injec-
tion. When down-staging was achieved the patient underwent
transplantation.
The variables were gender, age (years), and AFP level (ng/mL).
In the explanted liver we observed the presence of the following:
microvascular or macrovascular invasion, number of nodules and
their largest size, Edmondson-Steiner histological differentiation,
incidental tumor, TACE before transplantation, Milan criteria, and
down-staging. After OLT, patients were assessed at months 3, 6, 12,
and 24 using AFP serum levels and hepatic ultrasonography. If
tumor recurrence was suspected we performed abdominal CT.
Statistical Analysis
The Kaplan-Meier survival method was used to analyze survival
rates with log-rank tests. Cox proportional hazard regression was
used to evaluate predictive factors for tumor recurrence. A descrip-
tive statistic to characterize patients with versus without recurrence
used a nonparametric test (Kolmogorov-Smirnov). Statistically
significant differences were considered when P  .05.
RESULTS
Among 480 patients who underwent OLT at our depart-
ment, 83 had a preoperative diagnosis of HCC and 5 (6.0%)
experienced a tumor relapse at a mean time to diagnosis of
9 months. These subjects included 68 (82%) males and 15
(18%) females. The mean patient age at HCC recurrence
was 55.3 years for male and 44.6 years for female subjects.
The patient characteristics are summarized in Table 1.
Vascular invasion was detected in 17/83 (20.5%), namely
2% with macrovascular or microvascular invasion (Fig 1).
Among the cases 52.5% were classified as EMC due to the
number and size of nodules in the explanted livers. An
incidental tumor was observed in 29.5% of cases. Preoper-
Table 1. Characteristics of the Patients S
HCC Relapse
No. 5 (6.0%)
verage age (y) 51.3 (18–65)
V (1st/3rd y) 40%/0
ean of SV (mo) 10.1
FP (ng/mL) 54.6  113.1
argest nodule (mm) 28.3  12.6 (15–45)
MC 2/5
ncidental 0/5
ascular invasion 3/5Abbreviations: SV, survival rate; NS, not significant.tive TACE was performed in 13 (15.6%) patients, none of
hom displayed HCC recurrence.
The initial sites of recurrence were as follows: the liver
n  3), the lung (n  1) and multiple sites simultaneously
n  1). AFP level at the time of recurrence was around
,900 ng/mL. Overall cumulative and recurrence survival
re shown in Figure 2. Twenty-eight millimeters was the
utoff size that differentiated the risk of recurrence. The
redictive factor for mortality was the size of the nodules (P
.04; HR  0.0269; 95% confidence interval [CI], 0.0094–
.299).
In all cases, the treatment of a recurrence was systemic
hemotherapy with various schedules, including 1 patient
reated with Sorafenib. In all 5 patients tumor recurrence
as the cause of death with an average survival time of
bout 6 months.
DISCUSSION
Tumor recurrence is the cause of death among 3% to 26% of
cirrhotic patients with HCC who undergo transplantation .5–9 In
ur study the recurrence rate was 6%, similar to that
eported in the literature.2–12 The patients with recurrent
tted to OLT According to Relapse Tumor
Without Relapse Significance
78 (84%) —
54.2 (18–72) NS
86%/68% P  .04
39.1 P  .001
20.9  68.5 P  .03
23.2  13.2 (18–70) P  .001
39/78 NS
23/78 P  .051
14/78 P  .059
Fig 1. Microvascular invasion detected in explanted liver in
patient with recurrence tumor after transplantation (hematoxylin
eosin 400)—tumor cells within an endothelial lined-space.ubmi
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1364 ATAIDE, BOIN, ALMEIDA ET ALtumor showed a tendency to have greater vascular invasion
(P  .059) but not to have an incidental tumor (P  .051).
An important finding in our cohort was that the diameter of
nodule size in the explanted liver was an independent
predictor of HCC recurrence. The cutoff size to differenti-
ate the risk of recurrence was 28 mm (P  .001).
We observed a large number of cases with EMC (52.5%)
in their explanted livers. These up-staged patients have also
been observed by other authors6,8 who have suggested that
here may be an argument against further extending the
riteria for transplantation, as the staging accuracy may
eed to be improved first. In a previous study 7 we reported
42.2% of recipients to be under-staged, showing low accu-
racy of radiographic criteria, as also observed in the litera-
ture.6,8
Microvascular invasion is difficult to detect before HCC
treatment even if recent better imaging procedures are used
during patient evaluation. Although several studies have
suggested that the presence of microvascular invasion is an
independent factor predictive of poor survival after HCC
resection, the significance of microvascular invasion is still
unclear.3 In our study we observed just a tendency for this
premise. It is important to define the degree of microvas-
cular or macrovascular invasion, because some authors
include wall, muscle vessel, or contiguity with the liver
parenchyma, whereas others define microvascular invasion
as lesions visible only on microscopic examination.3,12
Shah et al2 related large tumor size and vascular invasion
o be correlated with poor survival, but there is a complex
nterplay among liver function, portal hypertension grade,
Fig 2. Cumulative proportional survival (Kaplan-Meier
ethod—log-rank test; P  .04) showing better survival in
patients without tumor relapse (No) when it was compared
with patients with relapse (Yes).nd host and tumor factors, which has been unclear.lthough we observed a tendency to find this association,
rognostic factors must be interpreted with caution.
Patients with incidental tumors showed similar survival
ates as those with known tumors in previous reports,2
which is consistent with our findings.
AFP was not a good tumor marker, because the median
level before transplantation was lower than the level at
diagnosis for candidacy on the waiting list; some authors
have searched for new HCC tumor markers.9,12
We evaluated the results of our 5 patients with HCC
recurrences after OLT by considering traditional and more
recently proposed, prognostic factors for HCC recurrence.
Other preoperative factors, such as tumor growth rate and
biological aggressiveness, need to be assessed because they
might predict the prognosis as well.
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